96982-61-5

Upstream product

• 1155705-57-9 diethyl 4-oxo-1-phenylbutylphosphonate 
• 1258145-84-4 C₁₆H₂₅O₅P 
• 1080-32-6 O,O-diethyl benzylphosphonate 

Downstream Products

• 1332895-41-6 dibenzyl {4-[(benzyloxy)(ethyl)amino]-4-oxo-1-phenylbutyl}phosphonate 
• 1332895-42-7 dibenzyl {4-[(benzyloxy)(propan-2-yl)amino]-4-oxo-1-phenylbutyl}phosphonate 
• 1332895-48-3 {4-[ethyl(hydroxy)amino]-4-oxo-1-phenylbutyl}phosphonic acid 
• 1332895-49-4 {4-[hydroxy(propan-2-yl)amino]-4-oxo-1-phenylbutyl}phosphonic acid 
• 1332895-37-0 diethyl {4-[(benzyloxy)(ethyl)amino]-4-oxo-1-phenylbutyl}phosphonate 
• 1332895-38-1 diethyl {4-[(benzyloxy)(propan-2-yl)amino]-4-oxo-1-phenylbutyl}phosphonate 
• 1258145-87-7 C₃₁H₃₂NO₅P 
• 1258145-88-8 C₁₀H₁₄NO₅P 
• 1258145-89-9 C₁₈H₂₂NO₅P 
• 1258145-90-2 C₁₁H₁₆NO₅P 
• 1258145-85-5 C₂₁H₂₈NO₅P 
• 1258145-86-6 C₂₂H₃₀NO₅P 

Relevant academic research and scientific papers

Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)

Reverse hydroxamate-based inhibitors of IspC, a key enzyme of the non-mevalonate pathway of isoprenoid biosynthesis and a validated antimalarial target, were synthesized and biologically evaluated. The binding mode of one derivative in complex with EcIspC

Synthesis and antiplasmodial activity of highly active reverse analogues of the antimalarial drug candidate fosmidomycin

Inhibition of enzymes involved in the nonmevalonate pathway of isoprenoid biosynthesis represents a promising strategy for the development of novel antimalarial agents. A small series of reverse hydroxamate-based fosmidomycin analogues was synthesized and evaluated for their inhibitory activity against the recombinant 1-deoxy-D-xylulose 5-phosphate reductoisomerases (DXRs) of Escherichia coli and Plasmodium falciparum, as well as for their in vitro antiplasmodial activity and cytotoxicity.